Explaining Naltrexone’s Interference With Ketamine’s Antidepressant Effect
To the Editor: In the December 2018 issue of the Journal, Williams and colleagues reported an unexpected attenuation of ketamine’s antidepressant effects by naltrexone (1). This finding represents an invaluable addition to our growing knowledge of ketamine’s therapeutic potential for depression; we would like to propose, however, that ketamine’s antidepressant effects are not mediated through direct opioid agonist activity. Neuromolecular data indicate that it may not be blockade of ketamine at the mu opioid receptor that stops the antidepressant effect, but rather that naltrexone at the mu opioid receptor enacts downstream signaling that interacts with the effects of ketamine.
It is recognized that N-methyl-d-aspartate (NMDA) receptors and mu opioid receptors are colocalized in many parts of the brain, serving as mutual regulators (2). This cross-regulation provides a parsimonious explanation for how naltrexone interferes with ketamine’s antidepressant activity: naltrexone antagonism of the mu opioid receptor increases cAMP, which interferes with ketamine’s activation of mammalian target of rapamycin (mTOR) (3, 4) (Figure 1). Numerous studies support mTOR activation as a crucial mediator of ketamine’s antidepressant effects (4–6) (Figure 2). Although ketamine ultimately leads to activation of mTOR through reduction of neuronal nitric oxide synthase (nNOS) activity, mu opioid receptor antagonism increases nNOS phosphorylation by cAMP, thus “hijacking” ketamine’s presumed antidepressant pathway. Naltrexone’s reversal of mu opioid receptors’ constitutive inhibition of cAMP subsequently leads to cAMP elevation and increases nNOS activity, ultimately preventing ketamine-induced formation of mTOR (Figure 3).
In summary, we present a mechanism, supported by two well-known pathways, through which naltrexone blocks ketamine’s antidepressant effect, and we add that this is possible without ketamine manifesting any opioid activity itself. Our conjecture further suggests that an adjunct cAMP or nNOS inhibitor, or an increase in neural mTOR signaling, might augment ketamine’s rapid and sustained antidepressant effect.
1 : Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018; 175:1205–1215Link, Google Scholar
2 : It’s MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol 2014; 5:116Crossref, Medline, Google Scholar
3 : Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance. Curr Drug Abuse Rev 2012; 5:199–226Crossref, Medline, Google Scholar
4 : Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry 2016; 21:313–319Crossref, Medline, Google Scholar
5 : Essential roles of neuropeptide VGF regulated TrkB/mTOR/BICC1 signaling and phosphorylation of AMPA receptor subunit GluA1 in the rapid antidepressant-like actions of ketamine in mice. Brain Res Bull 2018; 143:58–65Crossref, Medline, Google Scholar
6 : AMPA receptor-mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: insertion of AMPA receptor may play a role. Front Behav Neurosci 2015; 9:162Crossref, Medline, Google Scholar